Aptinyx
Evanston
Illinois
United States
128 articles about Aptinyx
-
Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020
7/8/2020
Aptinyx to Host PTSD-Focused R&D Day on August 5 th , 2020 Program to feature presentation from Dr. Murray Stein, Distinguished Professor of Psychiatry at UCSD and board-certified psychiatrist Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020 EVANSTON, Ill.--( BUSINESS WIRE )-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of bra
-
Aptinyx to be Added to Russell 2000® Index
6/26/2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US small-cap Russell 2000® Index. The addition will be effective after the US market opens on June 29, 2020 as part of the 2020 Russell US Indexes annual reconstitution. Inclusion in the Russell 2000® Index, which remains
-
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress DisorderData readout expected by late 2020
6/18/2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 to evaluate the safety and efficacy of NYX-783 in patients with post-traumatic stress disorder (PTSD). The company anticipates reporting data from the study in late 2020. “The completi
-
Aptinyx to Present at Upcoming Virtual Investor Conferences
6/16/2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following upcoming investor conferences: 2020 BMO Prescription for Success Healthcare Conference on Tuesday, June 23, 2020 at 2:30 p.m. ET and; SVB Leerink CybeRx Series: 2 nd Annual CNS Forum on Wednesda
-
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
5/14/2020
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020
-
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
4/30/2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 14, 2020 at 5:00 p.m. ET to report first quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 1-866-930-5579 (domestic)
-
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
3/30/2020
Aptinyx Inc. reported financial results for the fourth quarter and full year 2019 and provided updates across the company’s pipeline of novel NMDA receptor modulators.
-
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
3/18/2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Monday, March 30, 2020 at 5:00 p.m. ET to report fourth quarter and full year 2019 financial results and discuss recent business highlights.
-
Aptinyx to Present at Upcoming Investor Conferences - Feb. 19, 2020
2/19/2020
Aptinyx Inc. announced that company management will be presenting at the following investor conferences
-
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
1/30/2020
NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated with Parkinson’s disease
-
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
1/14/2020
Aptinyx Inc. announced the closing of its public offering of 11,691,666 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share.
-
Aptinyx Announces Pricing of Public Offering of Common Stock
1/10/2020
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its common stock at a public offering price of $3.00 per share.
-
Aptinyx Announces Proposed Public Offering of Common Stock - Jan. 9, 2020
1/9/2020
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
12/12/2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference
-
Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting
12/9/2019
The presentation is taking place today, December 9, 2019, at the Annual Meeting of the American College of Neuropsychopharmacology in Orlando, Florida.
-
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
12/5/2019
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2 clinical study of its novel NMDA receptor modulator, NYX-458, for the treatment of mild cognitive impairment associated with Parkinson’s disease.
-
Aptinyx to Present at Upcoming Investor Conferences
11/14/2019
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that company management will be presenting at the following investor conferences
-
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
11/12/2019
On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates
-
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
11/12/2019
200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications
-
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
11/5/2019
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that the company will host a conference call and live webcast on Tuesday, November 12, 2019 at 5:00 p.m. EST to report third quarter 2019 financial results and discuss recent business highlights.